SWOG Cancer Research Network
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, SWOG Cancer Research Network sits in the top decile of US sponsors by registered trial count (#125 of 15,742 sponsors by registered trial count).
SWOG Cancer Research Network: 270 sponsored US clinical trials, 28 recruiting.
SWOG Cancer Research Network sponsors 270 registered US clinical trials on ClinicalTrials.gov, 28 of them currently recruiting, and 181 completed. 68 of these trials are in Phase 3-4 (later-stage) and 164 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Lung Cancer, with 10 trials.
Top-decile sponsor footprint
SWOG Cancer Research Network ranks in the top decile of sponsors by registered trial count (#125 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
181 of 221 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
270 total, page 5 of 6
S0012 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Filgrastim in Treating Women With Inflammatory or Locally Advanced Breast Cancer
NCT00016406
S0101 Gemcitabine and Irinotecan in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus
NCT00012363
S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma
NCT00006721
S0022:Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage IIIB Non-Small Cell Lung Cancer
NCT00014196
S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract
NCT00014144
S9915 Triacetyluridine, Fluorouracil, and Leucovorin in Treating Patients With Unresectable, Locally Advanced, or Metastatic Cancer of the Esophagus or Stomach
NCT00004233
Combination Chemotherapy With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
NCT00006484
S0007 - Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
NCT00006248
S0004: Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Limited-stage Small Cell Lung Cancer
NCT00006487
S0019 Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00006708
S9925: Collecting and Storing Samples From Patients With Lung Cancer
NCT00920010
S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma
NCT00006237
S0010 506U78 in Treating Patients With Recurrent or Refractory Acute Lymphocytic Leukemia
NCT00006020
S9924 R115777 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
NCT00005832
S9923 R115777 in Treating Patients With Advanced Colorectal Cancer
NCT00005833
S0014 Combination Chemotherapy Plus Rituximab and Radiation Therapy in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma
NCT00005089
S9926 Temozolomide in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors
NCT00005597
S9901 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Men With Stage III or Stage IV Hodgkin's Disease
NCT00005090
S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma
NCT00005834
S9920 Busulfan Compared With Cyclophosphamide in Patients Undergoing Total-Body Irradiation Plus Peripheral Stem Cell Transplantation for Advanced Myelodysplastic Syndrome or Related Acute Myeloid Leukemia
NCT00005866
S9918 PSC 833, Daunorubicin, and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT00004217
S9902 Docetaxel Plus Carboplatin in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
NCT00003908
S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer
NCT00004124
S9914: Combination Chemotherapy Plus Filgrastim in Untreated Extensive-Stage Small Cell Lung Cancer
NCT00004137
S9900: Surgery With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer
NCT00004011
S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy
NCT00004001
S9912 Combination Chemo in Stage III Ovarian Cancer,
NCT00003896
S9903: Whole Brain Radiotherapy Followed By Stereotactic Radiosurgery for Limited Malignant Melanoma Brain Metastases
NCT00003911
S9911, Combination Chemotherapy Plus Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
NCT00003784
S9804: Vinorelbine in Treating Patients With Stage IV Melanoma
NCT00003828
S9910, Collecting and Storing Blood and Bone Marrow Samples From Patients With Hematologic Cancer
NCT00919425
S9809, Ciprofloxacin Compared With Cephalexin in Treating Patients With Bladder Cancer
NCT00003824
S9810: Gemcitabine Plus Cisplatin in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot Be Removed by Surgery
NCT00003723
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
NCT00003590
S9716: Combination Chemotherapy in Treating Patients With Merkel Cell Cancer
NCT00003549
S9806: Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
NCT00003587
S9805, High-Dose Melphalan Plus Peripheral Stem Cell Transplantation Followed by Interferon Alfa in Treating Patients With Waldenstrom's Macroglobulinemia
NCT00003416
S9717 Tirapazamine Plus Cisplatin in Treating Patients With Metastatic, Recurrent, or Refractory Cervical Cancer
NCT00003369
S9832: Effectiveness of Telephone Counseling By Breast Cancer Survivors on the Well-Being of Women With Recurrent Breast Cancer
NCT00031772
S9624 Ifosfamide in Treating Patients With Meningeal Tumors
NCT00003292
SWOG-S9635 Fluorouracil Plus Ethynyluracil in Advanced Colorectal Cancer Not Responded to Fluorouracil
NCT00003254
S9712: Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage III Non-small Cell Lung Cancer
NCT00003158
S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer
NCT00003127
SWOG-9507, Fenretinide in Treating Patients With Neoplasia of the Mouth
NCT00003223
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
NCT00003095
S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
NCT00003120
S9700 Combination Chemotherapy in Treating Patients With Stage II or Stage III Pancreatic Cancer
NCT00003018
S9709, Laser Surgery Plus Radiation Therapy in Treating Patients With Early Stage Cancer of the Larynx
NCT00003040
4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer
NCT00005047
SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma
NCT00004031
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 155 |
| Phase 3 | 68 |
Therapeutic Areas
What is open in the SWOG Cancer Research Network pipeline
28 recruiting of 270 indexed (10% open); 181 completed (67%).
Phase mix: 68 late (III/IV) vs 164 early (I/II) (early-phase heavy).
Top condition: Lung Cancer (10 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
SWOG Cancer Research Network: open-pipeline peers nationwide
Peers matched on 270 registered trials and 10% open enrollment, not the therapeutic-area sidebar.
SWOG Cancer Research Network sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 270 trials (± recruiting share)
- Alcon Research · 275 trials · 2% recruiting
- Novartis · 265 trials · 0% recruiting
- Abbott Medical Devices · 261 trials · 9% recruiting
- Boston Scientific Corporation · 280 trials · 8% recruiting
Sponsors near 10% open enrollment (± trial volume)
- California Pacific Medical Center Research Institute · 10% recruiting · 29 trials
- National Institute of Environmental Health Sciences (NIEHS) · 10% recruiting · 145 trials
- University of Rhode Island · 10% recruiting · 29 trials
- University of Mississippi Medical Center · 10% recruiting · 96 trials
Related
What to do with this SWOG Cancer Research Network page
270 registered trials is a research-attention snapshot, not an endorsement of SWOG Cancer Research Network or any single study.
- 28 of SWOG Cancer Research Network's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Lung Cancer is the condition SWOG Cancer Research Network studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Lung Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. SWOG Cancer Research Network pipeline card: 270 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.